🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchClinicalTrials.gov GLP-1 trial tracker — updated weekly Page 7

ClinicalTrials.gov GLP-1 trial tracker — updated weekly

TrialTracker_MD Mon, Feb 26, 2024 at 4:00 PM 411 replies 11,865 viewsPage 7 of 20
paige_pharma
Member
289
1,234
Sep 2024
Omaha, NE
Jun 13, 2024 at 4:06 PM#31

Clinical perspective, offered as context rather than as advice. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

Last edited: Jun 13, 2024 at 5:06 PM
9 7rachel_ABQ, traveltech_sara, AttorneyGrant and 6 others
Reply Quote Save Share Report
chris_chi24
Member
389
1,678
Sep 2024
Chicago, IL
Jun 22, 2024 at 4:09 AM#32
paige_pharma said:
Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…

Second this.

10 8MounjBrad, nick_newbie, DadBodDave and 7 others
Reply Quote Save Share Report
robert_kc
Member
289
1,234
Oct 2024
Kansas City, MO
Jun 30, 2024 at 4:07 PM#33
paige_pharma said:
Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…

Coming at paige_pharma’s question from a different direction. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

11 9DoseLogDan, SleepFixSam, PurityPaulOR and 8 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Jul 9, 2024 at 4:00 AM#34

The figures, for anyone assembling their own picture. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

Last edited: Jul 9, 2024 at 5:00 AM
12 10DebRD_ATL, KristenIndy, MarkLI_maint and 9 others
Reply Quote Save Share Report
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Jul 17, 2024 at 3:48 PM#35

One thing that is still open after paige_pharma’s answer:

Was that from a primary source or from a summary of one?

13 11Dr.RaviCardio, jennifer_SEA, tyler_CSCS and 10 others
Reply Quote Save Share Report
15678920

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register